Breast Cancer
A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)
- Details
ClinicalTrials.gov ID:
NCT06449222
Diagnosis Type:
NA
USOR Number:
- Address
,
P: